Genmab A/S's Form 4 filing
Merus N.V. (MRUS) · filed Dec 30, 2025
- Accession no.
- 0001193125-25-337324
- Filed
- Dec 30, 2025
- Trade date
- Dec 26-29, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $7.46B. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Genmab A/SCIK 0001434265 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 26, 2025 | Common Shares, nominal value EUR 0.09 per share | PPurchaseAcquired | +2,978 | $97.00 | +$288,866 | 72,831,487 | Indirect | |
| Dec 29, 2025 | Common Shares, nominal value EUR 0.09 per share | PPurchaseAcquired | +1,052,806 | $97.00 | +$102,122,182 | 73,884,293 | Indirect | |
| Dec 29, 2025 | Common Shares, nominal value EUR 0.09 per share | PPurchaseDisposed | −75,867,199 | $97.00 | −$7,359,118,303 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.